Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Germline-Targeting Strategies to Induce bNAbs against HIV-1.

Created on 13 Aug 2026

Authors

Tugba Atabey, Rogier W Sanders, Yoann Aldon

Published in

Current HIV research. Volume 23. Issue 6. Pages 456-481.

Abstract

Developing an effective HIV-1 vaccine remains a critical global health challenge, hindered by the virus's high genetic diversity, immune evasion strategies, and structural complexity of its Envelope (Env) glycoprotein. Broadly neutralizing antibodies (bNAbs), capable of targeting conserved Env epitopes, offer a promising path for vaccine design. Germline-Targeting (GT) strategies have emerged as a promising approach to engage naive B cell precursors that have the potential to mature into bNAb-producing cells. Advances in GT have enabled the design of immunogens capable of recruiting specific bNAb precursors in animal models and early clinical trials. Despite these successes, achieving neutralization breadth requires sequential immunizations with tailored boosting strategies to guide B cell maturation. Studies underscore the importance of using immunogens that mimic native Env structures while modulating glycosylation patterns to focus immune responses. Emerging approaches, such as membrane-bound presentation and mRNA delivery, hold the potential for enhancing immunogen effectiveness and rapid pre-clinical and in human screening to identify combinations of immunogens that foster bNAb lineages. This review seeks to synthesize key developments in GT strategies for HIV-1 vaccines, highlighting the design and implementation of immunogens that drive bNAb precursor maturation. It aims to underscore the importance of integrating structural insights, immunogen sequence design, and delivery methods to enhance the induction of bNAbs, offering direction for future research to address existing gaps and optimize vaccine efficacy.

PMID:
40511646
Bibliographic data and abstract were imported from PubMed on 13 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement